34 results about "Hantaan virus" patented technology

The invention discloses a neutralizing monoclonal antibody 3D8 identified HTNV-GP specific B cell epitope and key amino acid residue sequence of the epitope for treating hemorrhagic fever with renal syndrome (HFRS) caused by hantaan virus (HTNV) infection. The B cell epitope has an amino acid sequence of 882GFLCPEFPGSFRKKC896. The epitope peptide can be applied to study of mechanism of 3D8 neutralizing monoclonal antibody in treatment of HFRS, or preparation of drug for treating HFRS and preparation of novel vaccine strain aiming at hantaan virus 76-118, or development of novel diagnostic kitfor hantaan virus 76-118 as a target protein. The invention has good prospects of development and application in the field of HFRS specific immunotherapy.

The invention discloses application of a medicine in resisting Hantaan viruses, namely arbidol. The arbidol has obvious effect of inhibiting the Hantaan viruses in vitro, and the antivirus effect of drug administration before the viruses enter a cell is stronger than that of the drug administration after the viruses enter the cell. The concrete embodiment comprises the following: the drug administration is performed before and after the infection, the positive rate of virus-infected cells and the fluorescence intensity are reduced along with the concentration increase, and the medicine has dosage effect; and the medicine can obviously reduce the positive rate of virus infection, and the mRNA expression of the viruses is reduced. The arbidol has protection and treatment effect on the infection of the Hantaan viruses on a suckling mouse, and the protection effect is stronger than the treatment effect. The drug administration is performed within 24h before the infection; and with the increase of the dosage of the medicine, the death rate of the mouse is reduced, and the average survival days are extended. The drug administration within 24h after the infection can not improve the survival rate of an animal, but can extend the average survival days of the animal. The arbidol has the effect of inhibiting the Hantaan viruses in a body of the animal. The drug administration within 24h before the infection can lighten the pathologic change of tissues (lung, kidney, and brain), and has treatment effect on HFRS. The medicine has prevention effect and also has treatment effect on patients with the hemorrhagic fever with renal syndrome (HFRS) caused by the Hantaan viruses, and no toxic side effect is found.

The invention discloses RT-LAMP (reverse transcription loop-mediated isothermal amplification) nucleic acid detection primers and a kit of Hantaan viruses and in particular relates to a group of primers for detecting Hantaan viruses, a kit containing the primers and a detection method of the Hantaan viruses. The primers comprise base sequences shown in a sequence table SEQ ID No.1 to a sequence table SEQ ID No.6. The kit has high sensitivity and strong specificity, is low in cost and is simple and convenient to operate.

The invention discloses an SYBR Green I Real-time PCR (Real-time fluorescent quantitative polymerase chain reaction) method for quickly detecting and indentifying Hantaan virus infection. The method comprises the following steps: designing a pair of specific primers mainly according to a conserved sequence of an S gene in a GenBank database; using a positive plasmid subjected to 10-time gradient dilution as a standard product; optimizing a reaction condition; establishing the SYBR Green I Real-time PCR method used for detecting a Vero E6 cell, a mouse and a clinical patient, which are infected by Hantaan virus nucleic acids according to qRT-PCR specificity amplification, wherein a copy number of the detection sensitivity can reach 101, and sensitivity, repeatability and specificity of the Hantaan virus nucleic acids are detected. Compared with a conventional Hantaan virus detection method, the method has the advantages that types of detecting samples are rich, the application range is wide, the contrast is strong, operation steps are relatively few, convenience and quickness are realized, the sensitivity and the repeatability are high, the specificity is good, and a linear relationship is good, and can provide a strong experimental basis on clinical and laboratory detection of hemorrhagic fever with renal syndrome as well as studying of epidemiology.

The invention discloses an HTNV-Gn / Gc specific T cell epitope peptide and an application thereof. The amino acid sequence of the HTNV-Gn / Gc specific T cell epitope peptide is one selected from SEQ ID NO. 1 to SEQ ID NO. 75. The HTNV-Gn / Gc specific T cell epitope peptide comprises CD4<+>T cell epitope and CTL epitope, and can respectively induce CD4<+>T cell and CD8<+>T cell to generate intensive cellular immunologic response and to secrete high-level IFN-gamma. The HTNV-Gn / Gc specific T cell epitope peptide can be used in the preparation of T cell epitope peptide vaccines, and can be used in inducing CD4<+>T cell or cytotoxicity T cell generating epitope peptide specificity. Therefore, the HTNV-Gn / Gc specific T cell epitope peptide has a good exploitation and application prospect in the field of HFRS specific immunotherapy.

The invention relates to a nucleic acid set, a kit and a detection method for detecting Hantaan viruses through RPA (recombinase polymerase amplification). The nucleic acid set comprises a primer pairand a probe. The primer pair comprises a forward primer and a reverse primer, the sequence of the forward primer is SEQ ID NO. 2, the sequence of the reverse primer is SEQ ID NO. 3, and the sequenceof the probe is SEQ ID NO. 4. The kit comprises the nucleic acid set, and is applied to the detection method. Amplification can be realized at a temperature near to the body temperature, and visual discrimination of amplified products can be realized by a disposable nucleic acid detecting device. The nucleic acid set, the kit and the detection method have the advantages of high sensitivity and specificity, low requirement on hardware equipment, short reaction time, no complicated treatment on samples, suitability for on-site detection and the like, and are suitable for popularization and application.

The invention discloses a method for detecting hantaan virus strain genome. The method has the following steps: (1) two pairs of hantaan virus general primers are designed; (2) the hantaan virus detection method comprises the following steps that: first, viral specific RNA extraction kit is utilized to extract the total RNA in a serum sample; second, a nucleic acid analyzer is adopted to detect the RNA content, and the RNA is taken to perform the RT-PCR reaction; third, RT-PCR:RT uses HV group-specific primers such as P0, PCR uses HV general primers such as P1P2 and P3P4; fourth, viral nucleic acid amplified results are observed through agarose gel electrophoresis, and a specific nucleic acid band appears. The method is intuitionistic and predominant, the sensibility is good, and the effects are good; the serum detection rate in recent ten years is 79.2 percent, and the serum detection rate in twenty years ago can still reach to 70.5 percent; the method is applied to the laboratory detection of hantaan virus infection and the molecular epidemiological survey.

The invention discloses a SYBR GreenⅠReal-time PCR method for rapid detection and identification of Hantaan virus infection. The method mainly designs a pair of specific primers based on the sequence of the conserved region of the S gene in the GenBank database. The gradient diluted positive plasmid was used as the standard, the reaction conditions were optimized, and the specific amplification by qRT-PCR was used to establish the SYBR Green Ⅰ Real-time PCR method for the detection of Hantaan virus nucleic acid in infected Vero E6 cells, infected mice and clinical patients, and the detection sensitivity A copy number of 101 was reached and tested for sensitivity, reproducibility, and specificity. Compared with conventional Hantaan virus detection and identification methods, this method has the advantages of rich types of detection specimens, wide application range, strong contrast, few operation steps, convenient and fast, high sensitivity, high repeatability and specificity, and has good The advantage of a linear relationship. It provides a strong experimental basis for the clinical, laboratory detection and epidemiological research of hemorrhagic fever with renal syndrome.

A synthetic, codon-optimized Hantaan virus (HTNV) full-length M gene open reading frame that consists of a unique nucleotide sequence encoding HTNV proteins. This synthetic gene was cloned into a plasmid to form the first optimized HTNV full-length M gene that elicits neutralizing antibodies in animals when delivered in combination with a similarly optimized Puumala virus (PUUV) DNA vaccine. The invention obviates the need for an extraneous gene sequence that was previously required for expression of the non-optimized HTNV gene. The synthetic gene is engineered into a molecular vaccine system to prevent hemorrhagic fever with renal syndrome (HFRS) caused by infection with HTNV, SEOV, or DOBV. Alternatively, it can be combined with the optimized PUUV DNA vaccine to protect against HFRS caused by any hantavirus.

Azole nucleosides represented by the formulae (I) and (II); wherein A = C or N B = C or N X = H; C1-C6 alkyl, cycloalkyl, alkenyl, cycloalkenyl, alky nyl, aryl, heterocyclo, halogen such as F, C1, Br and I; OH, NH2, NH-(C1-C6 alkyl, cycloalkyl, aryl, or heterocyclo); Z = H; C1-C6 alkyl, cycloalkyl, al kenyl, cycloalkenyl, alkynyl, aryl, heterocyclo, halogen such as F, Cl, Br, I; OH, NH2, NH-(C1-C6 alkyl, cycloalkyl, aryl, or heterocyclo; E= (CH2)HONHR 1; n is an integer from 0-6 and more typically 0-3; R1= aryl or heterocyclo; each of W, Y, R is individually selected from the group consisting of H; C1 -C6 alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclo; ha logen such as F, Cl, Br, and I; O, OH, Oalkyl, Oaryl, NH2, NH-(C1-C6 alkyl, cycloalkyl, aryl, or heterocyclo); provided that at least one of W, Y, and R is other than H and wherein both W and Y together can be =O; and each D ind ividually is OH, Oalkyl, Oaryl, Fl and H;pharmaceutically acceptable salts t hereof, prodrugs thereof and mixtures thereof are provided. Compounds of thi s disclosure are useful as inhibitors of viral RNA and DNA polymerases such as, but not limited to, Influenza, Hantaan Virus, Crimean Congo hemorrhagic fever virus, hepatitis B, hepatitis C, Polio, Coxsackie A and B, Rhino, Echo , orthopoxvirus (small pox), HIV, Ebola, and West Nile virus polymerases; an especially orthopoxvirus, HIV, and hepatitis B.

The invention belongs to the field of genetic engineering and discloses a haynaldia villosa disulfide isomerase gene and an application thereof. The cDNA (complementary deoxyribonucleic acid) sequence of Hv-PDI (Hantaan Virus-Protein Disulfide Isomerase) is SEQ ID NO. 1, and the encoded amino acid sequence is SEQ ID NO. 2. The gene derives from diploid haynaldia villosa (haynaldia villosa VV, 2n=14), is induced by powdery mildew in powdery mildew-resistant diploid haynaldia villosa, and is greatly expressed. Through transient expression, the gene is transformed to an infected wheat variety Yangmai 158, a result shows that excessive expression of Hv-PDI is capable of reducing the haustorium index of Yangmai 158. Therefore, the Hv-PDI is expectedly used for genetic engineering breeding, and the resistance of wheat to powdery mildew is hopefully improved when the Hv-PDI is introduced to wheat varieties susceptible to powdery mildew.

The invention discloses a neutralizing monoclonal antibody 3D8 identified HTNV-GP specific B cell epitope and key amino acid residue sequence of the epitope for treating hemorrhagic fever with renal syndrome (HFRS) caused by hantaan virus (HTNV) infection. The B cell epitope has an amino acid sequence of 882GFLCPEFPGSFRKKC896. The epitope peptide can be applied to study of mechanism of 3D8 neutralizing monoclonal antibody in treatment of HFRS, or preparation of drug for treating HFRS and preparation of novel vaccine strain aiming at hantaan virus 76-118, or development of novel diagnostic kit for hantaan virus 76-118 as a target protein. The invention has good prospects of development and application in the field of HFRS specific immunotherapy.

The invention discloses the application of benzopyran compounds for preparing anti-Hantaan virus drugs. It is found in the present invention that the structural compound represented by formula I has good in vitro activity, and has a strong inhibitory effect on anti-Hantaan virus.

The invention discloses HTNV-NP (Hantaan virus nucleoprotein)-specific CTL (cytotoxic T lymphocyte) epitope peptides and application thereof. The CTL epitope peptides have amino acid sequences shown in SEQ ID NO:1-12. Especially, HLA-I (human leucocyte antigen-I) molecule restricted epitope polypeptide in the HTNV-NP-specific CTL epitope peptides can induce CD8+T lymphocyte to generate strong cellular immune response and secrete high-level IFN-gamma. The HTNV-NP-specific CTL epitope peptides can be used for preparing CTL epitope peptide vaccines or for inducing the generation of CTL epitope peptide-specific CTL, or for preparing CTL epitope peptide-sensitized antigen presenting cells and have bright development and application prospects in the field of specific immunization therapy of HFRS (hemorrhagic fever with renal syndrome).

The invention relates to a hantaan virus-like particle containing GM-CSF as well as a preparation method and application of hantaan virus-like particles. For the VLP (virus-like particle) composed of multiple proteins, baculoviruses for expressing all proteins are required to be prepared on the basis of an insect cell expression system, and then insect cells are co-infected according to different proportions, so that a lot of work for exploring a co-infection proportion is required, and in addition, a certain difficulty is brought to purification in a later period due to baculoviruses mixed in the product. According to the invention, on the basis of a mammalian cell expression system, by constructing a eukaryotic expression vector to co-transfect dhfr-CHO cells, and the hantaan virus-like particle containing GM-CSF is assembled. According to the invention, all components of the chimeric virus like particle can express, the constructed eukaryotic expression vector contains multiple selection markers, a cell strain for stably expressing chimeric virus like particles can be constructed through screening, mass production and preparation are facilitated and the hantaan virus-like particle can be used for preventing hemorrhagic fever with renal syndrome, which is caused by hantaan virus infection.

The invention discloses a high-flux method for quickly detecting hantaan virusneutralizing antibody titer. The method is characterized by utilizing an In-cell Western (ICW) method for simply, conveniently and intuitively detecting cells infected by HTNV (Hantaan Virus). The method is high in detection sensitivity (capable of detecting 5g of target protein), short in period (72 hours), objective in result interpretation, good in repetitiveness, high in flux, standardized in method, and convenient to inter-laboratory popularize, and can be particularly used for detecting the infectivity of acellular cytopathic effect virus. The invention also discloses application of the method in HTNV infectivity titration (TCID50), HTNV neutralizing antibody titration, anti-HTNV molecular screening and identification, human HTNV vaccine immunity protection evaluation and the like.

The invention relates to a hantaan virus-like particle containing GM-CSF as well as a preparation method and application of hantaan virus-like particles. For the VLP (virus-like particle) composed of multiple proteins, baculoviruses for expressing all proteins are required to be prepared on the basis of an insect cell expression system, and then insect cells are co-infected according to different proportions, so that a lot of work for exploring a co-infection proportion is required, and in addition, a certain difficulty is brought to purification in a later period due to baculoviruses mixed in the product. According to the invention, on the basis of a mammalian cell expression system, by constructing a eukaryotic expression vector to co-transfect dhfr-CHO cells, and the hantaan virus-like particle containing GM-CSF is assembled. According to the invention, all components of the chimeric virus like particle can express, the constructed eukaryotic expression vector contains multiple selection markers, a cell strain for stably expressing chimeric virus like particles can be constructed through screening, mass production and preparation are facilitated and the hantaan virus-like particle can be used for preventing hemorrhagic fever with renal syndrome, which is caused by hantaan virus infection.

The invention discloses a mucosa immune vaccine of hemorrhage fever syndrome and a preparation method thereof. The vaccine comprises inactivated virus and chitosan from hantaan virus which can cause hemorrhage fever syndrome in one or a plurality of types, wherein the chitosan exists in the form of micro-particles; the inactivated virus is covered inside the micro-particles of chitosan; furthermore, the vaccine can fruther comprise escherichia coli heat-labile enterotoxin B subunit with mucosa adjuvant activity; the result of the animal experiment shows that the vaccine of the invention can effectively excite the immune response of specific mucosa and the body fluid of the body anti-hantaan virus through nasal cavity and oral administration. The vaccine has statistical significance compared with the control group (p is less than 0.01) and has the advantages of safety, convenience, cost-effeciveness etc., compared with traditional hemorrhagic fever injected vaccine.